공지 : 도쿄증권거래소 JASDAQ 스탠다드 시장 신규 상장 관련 안내

Global Information
회사소개 | 문의 | 비교리스트

Rho 관련 단백질 키나아제 2 : 파이프라인 리뷰

Rho Associated Protein Kinase 2 - Pipeline Review, H2 2019

리서치사 Global Markets Direct
발행일 2019년 12월 상품 코드 410996
페이지 정보 영문 64 Pages
가격
US $ 3,500 ₩ 3,945,000 PDF (Single user license) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 7,000 ₩ 7,891,000 PDF (Site license) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 10,500 ₩ 11,836,000 PDF (Global license) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


Rho 관련 단백질 키나아제 2 : 파이프라인 리뷰 Rho Associated Protein Kinase 2 - Pipeline Review, H2 2019
발행일 : 2019년 12월 페이지 정보 : 영문 64 Pages

본 상품은 영문 자료로 한글과 영문목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

Rho 관련 단백질 키나아제 2(Rho Associated Protein Kinase 2)를 표적으로 한 치료제 개발 파이프라인 현황과 최신 업데이트에 의한 각 개발 단계 비교 분석, 기업과 연구기관이 개발중인 치료제, 치료제 평가, 후기 단계 및 중지된 프로젝트 관련 정보, 최신 뉴스와 발표 등의 정보를 전해드립니다.

서론

  • 조사 범위

Rho 관련 단백질 키나아제 2 개요

치료제 개발

  • 개발중인 제품 : 개발 단계별
  • 개발중인 제품 : 치료 영역별
  • 개발중인 제품 : 증상별

파이프라인 제품 상황 개요

  • 후기 단계 제품
  • 초기 단계 제품

기업에서 개발중인 제품

치료제 평가

  • 단독치료 제품/병용요법 제품별
  • 작용기전별
  • 투여 경로별
  • 분자 종류별

치료제 개발 참여기업

  • Anacor Pharmaceuticals Inc
  • Astex Pharmaceuticals Inc
  • BioAxone BioSciences Inc
  • HitGen LTD
  • Kadmon Corp LLC
  • Vertex Pharmaceuticals Inc
  • Vichem Chemie Research Ltd

약제 개요

  • AN-3485
  • AT-13148
  • BA-1049
  • BA-1076
  • KD-025
  • KL-00148
  • Small Molecule to Inhibit Rho-associated protein kinase 2
  • Small Molecule to Inhibit ROCK-2 for Cardiovascular, Ophthalmology and Oncology
  • Small Molecules to Selectively Inhibit ROCK2 for Autoimmune Disorders
  • TRN-101
  • TRX-101
  • VX-210

휴지 상태인 프로젝트

개발이 중지된 제품

주요 뉴스 및 프레스 릴리스

부록

도표

LSH 17.02.27

List of Tables

  • Number of Products under Development by Stage of Development, H2 2019
  • Number of Products under Development by Therapy Areas, H2 2019
  • Number of Products under Development by Indication, H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Products under Development by Companies, H2 2019
  • Products under Development by Companies, H2 2019 (Contd..1), H2 2019
  • Number of Products by Stage and Mechanism of Actions, H2 2019
  • Number of Products by Stage and Route of Administration, H2 2019
  • Number of Products by Stage and Molecule Type, H2 2019
  • Pipeline by AbbVie Inc, H2 2019
  • Pipeline by Angion Biomedica Corp, H2 2019
  • Pipeline by Astex Pharmaceuticals Inc, H2 2019
  • Pipeline by BioAxone BioSciences Inc, H2 2019
  • Pipeline by HitGen LTD, H2 2019
  • Pipeline by Kadmon Corp LLC, H2 2019
  • Pipeline by Redx Pharma Plc, H2 2019
  • Pipeline by Theratrophix LLC, H2 2019
  • Dormant Products, H2 2019
  • Dormant Products, H2 2019 (Contd..1), H2 2019
  • Discontinued Products, H2 2019

List of Figures

  • Number of Products under Development by Stage of Development, H2 2019
  • Number of Products under Development by Therapy Areas, H2 2019
  • Number of Products under Development by Top 10 Indications, H2 2019
  • Number of Products by Stage and Mechanism of Actions, H2 2019
  • Number of Products by Routes of Administration, H2 2019
  • Number of Products by Stage and Routes of Administration, H2 2019
  • Number of Products by Stage and Molecule Type, H2 2019

Summary

Rho Associated Protein Kinase 2 (Rho Kinase 2 or Rho Associated Coiled Coil Containing Protein Kinase 2 or p164 ROCK 2 or ROCK2 or EC 2.7.11.1) - Rho-Associated Protein Kinase 1 (ROCK1) is a protein serine/threonine kinase. It is a key regulator of actin cytoskeleton and cell polarity. It is involved in regulation of smooth muscle contraction, actin cytoskeleton organization, stress fiber and focal adhesion formation, neurite retraction, cell adhesion and motility via phosphorylation of DAPK3, GFAP, LIMK1, LIMK2, MYL9/MLC2, PFN1 and PPP1R12A. It phosphorylates JIP3 and regulates the recruitment of JNK to JIP3 upon UVB-induced stress. It acts as a suppressor of inflammatory cell migration by regulating PTEN phosphorylation and stability. It acts as a negative regulator of VEGF-induced angiogenic endothelial cell activation.

Rho Associated Protein Kinase 2 (Rho Kinase 2 or Rho Associated Coiled Coil Containing Protein Kinase 2 or p164 ROCK 2 or ROCK2 or EC 2.7.11.1) pipeline Target constitutes close to 13 molecules. The molecules developed by companies in Phase II, Phase I and Preclinical stages are 1, 1 and 11 respectively. Report covers products from therapy areas Gastrointestinal, Respiratory, Genito Urinary System And Sex Hormones, Cardiovascular, Immunology, Ophthalmology, Central Nervous System, Metabolic Disorders, Musculoskeletal Disorders, Non Malignant Disorders and Oncology which include indications Idiopathic Pulmonary Fibrosis, Chronic Kidney Disease (Chronic Renal Failure), Glaucoma, Kidney Fibrosis, Non-Alcoholic Steatohepatitis (NASH), Stroke, Acute Renal Failure (ARF) (Acute Kidney Injury), Cavernous Hemangioma (Cerebral Cavernous Malformation/Cerebral Cavernous Hemangioma), Chronic Obstructive Pulmonary Disease (COPD), Crohn's Disease (Regional Enteritis), Diabetic Nephropathy, Fibrosis, Graft Versus Host Disease (GVHD), Inflammation, Liver Fibrosis, Pain, Plaque Psoriasis (Psoriasis Vulgaris), Rheumatoid Arthritis, Solid Tumor and Systemic Sclerosis (Scleroderma).

The latest report Rho Associated Protein Kinase 2 - Pipeline Review, H2 2019, outlays comprehensive information on the Rho Associated Protein Kinase 2 (Rho Kinase 2 or Rho Associated Coiled Coil Containing Protein Kinase 2 or p164 ROCK 2 or ROCK2 or EC 2.7.11.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Rho Associated Protein Kinase 2 (Rho Kinase 2 or Rho Associated Coiled Coil Containing Protein Kinase 2 or p164 ROCK 2 or ROCK2 or EC 2.7.11.1) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Rho Associated Protein Kinase 2 (Rho Kinase 2 or Rho Associated Coiled Coil Containing Protein Kinase 2 or p164 ROCK 2 or ROCK2 or EC 2.7.11.1)
  • The report reviews Rho Associated Protein Kinase 2 (Rho Kinase 2 or Rho Associated Coiled Coil Containing Protein Kinase 2 or p164 ROCK 2 or ROCK2 or EC 2.7.11.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Rho Associated Protein Kinase 2 (Rho Kinase 2 or Rho Associated Coiled Coil Containing Protein Kinase 2 or p164 ROCK 2 or ROCK2 or EC 2.7.11.1) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Rho Associated Protein Kinase 2 (Rho Kinase 2 or Rho Associated Coiled Coil Containing Protein Kinase 2 or p164 ROCK 2 or ROCK2 or EC 2.7.11.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Rho Associated Protein Kinase 2 (Rho Kinase 2 or Rho Associated Coiled Coil Containing Protein Kinase 2 or p164 ROCK 2 or ROCK2 or EC 2.7.11.1) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Rho Associated Protein Kinase 2 (Rho Kinase 2 or Rho Associated Coiled Coil Containing Protein Kinase 2 or p164 ROCK 2 or ROCK2 or EC 2.7.11.1)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Rho Associated Protein Kinase 2 (Rho Kinase 2 or Rho Associated Coiled Coil Containing Protein Kinase 2 or p164 ROCK 2 or ROCK2 or EC 2.7.11.1) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • Rho Associated Protein Kinase 2 (Rho Kinase 2 or Rho Associated Coiled Coil Containing Protein Kinase 2 or p164 ROCK 2 or ROCK2 or EC 2.7.11.1) - Overview
  • Rho Associated Protein Kinase 2 (Rho Kinase 2 or Rho Associated Coiled Coil Containing Protein Kinase 2 or p164 ROCK 2 or ROCK2 or EC 2.7.11.1) - Therapeutics Development
  • Products under Development by Stage of Development
  • Products under Development by Therapy Area
  • Products under Development by Indication
  • Products under Development by Companies
  • Rho Associated Protein Kinase 2 (Rho Kinase 2 or Rho Associated Coiled Coil Containing Protein Kinase 2 or p164 ROCK 2 or ROCK2 or EC 2.7.11.1) - Therapeutics Assessment
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Rho Associated Protein Kinase 2 (Rho Kinase 2 or Rho Associated Coiled Coil Containing Protein Kinase 2 or p164 ROCK 2 or ROCK2 or EC 2.7.11.1) - Companies Involved in Therapeutics Development
  • AbbVie Inc
  • Angion Biomedica Corp
  • Astex Pharmaceuticals Inc
  • BioAxone BioSciences Inc
  • HitGen LTD
  • Kadmon Corp LLC
  • Redx Pharma Plc
  • Theratrophix LLC
  • Rho Associated Protein Kinase 2 (Rho Kinase 2 or Rho Associated Coiled Coil Containing Protein Kinase 2 or p164 ROCK 2 or ROCK2 or EC 2.7.11.1) - Drug Profiles
  • ANG-4201 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • AT-13148 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • BA-1049 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • BA-1076 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • BA-2017 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • KD-025 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • KD-045 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • REDX-08397 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • REDX-8087 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecule to Inhibit ROCK-2 for Cardiovascular, Metabolic Disorders, Ophthalmology and Oncology - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecule to Inhibit ROCK2 for Fibrotic Diseases - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Inhibit ROCK1 and ROCK 2 for Pain - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • TRX-101 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Rho Associated Protein Kinase 2 (Rho Kinase 2 or Rho Associated Coiled Coil Containing Protein Kinase 2 or p164 ROCK 2 or ROCK2 or EC 2.7.11.1) - Dormant Products
  • Rho Associated Protein Kinase 2 (Rho Kinase 2 or Rho Associated Coiled Coil Containing Protein Kinase 2 or p164 ROCK 2 or ROCK2 or EC 2.7.11.1) - Discontinued Products
  • Rho Associated Protein Kinase 2 (Rho Kinase 2 or Rho Associated Coiled Coil Containing Protein Kinase 2 or p164 ROCK 2 or ROCK2 or EC 2.7.11.1) - Product Development Milestones
  • Featured News & Press Releases
  • Dec 16, 2019: BioAxone BioSciences expands patent for treatment of Cerebral Cavernous Malformations and Cerebral Aneurysms with Rho kinase inhibitors
  • Dec 03, 2019: Kadmon to present updated data from phase 2 study of KD025 in cGVHD at the 61st ASH Annual Meeting & Exposition
  • Nov 19, 2019: Redx Pharma and Medicines Discovery Catapult awarded grant for biomarker project including Small Molecule to Inhibit ROCK2 for Fibrotic Diseases
  • Sep 12, 2019: BioAxone BioSciences announces publication in Translational Stroke Research of Cavernous Angioma Disease Research Article
  • Aug 13, 2019: Kadmon fully enrolls pivotal trial of KD025 for Chronic Graft-Versus-Host Disease
  • Aug 13, 2019: Kadmon fully enrolls pivotal trial of KD025 for Chronic Graft-Versus-Host Disease
  • Jul 09, 2019: Kadmon doses first patient in phase 2 clinical trial of KD025 in Systemic Sclerosis
  • Feb 12, 2019: Redx Pharma: New in vivo data suggests ROCK2 has broad potential in fibrosis
  • Dec 03, 2018: Kadmon announces updated findings from ongoing phase 2 clinical trial of KD025 in cGVHD at ASH Annual Meeting
  • Nov 29, 2018: Kadmon presents data on New ROCK Inhibitor clinical candidate at Anti-Fibrotic Drug Development Summit
  • Nov 01, 2018: Kadmon announces oral presentation on KD025 in Chronic Graft-Versus-Host Disease at ASH Annual Meeting
  • Oct 26, 2018: Redx announces details from the ROCK2 inhibitor poster presented at the ASN Kidney Week 2018 in San Diego
  • Oct 25, 2018: Kadmon initiates pivotal phase 2 trial of KD025 in chronic graft-versus-host disease
  • Oct 22, 2018: Redx ROCK2 inhibitors poster to be presented at the ASN Kidney Week 2018 in San Diego
  • Oct 17, 2018: FDA grants breakthrough therapy designation to Kadmon's KD025 for chronic graft-versus-host disease
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer
Back to Top
전화 문의
F A Q